goodrx novo nordisk - Search News

News

Novo Nordisk, GoodRX, CVS

Barron's on MSN · 14h

Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.

Shares of GoodRx were spiking 35% on Monday. The announcement followed news from Novo Nordisk that the Food and Drug Administration had approved Wegovy for treatment of a serious form of liver disease. Shares of the Danish drugmaker were rising 4.9% in U.S. trading.

Reuters on MSN · 12h

Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.

Yahoo Finance · 8h

GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.

13hon MSN

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

11h

GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning?

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results